Cargando…
Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573475/ https://www.ncbi.nlm.nih.gov/pubmed/34738840 http://dx.doi.org/10.1177/15330338211049902 |
| _version_ | 1784595432692776960 |
|---|---|
| author | Tong, Wing H. |
| author_facet | Tong, Wing H. |
| author_sort | Tong, Wing H. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8573475 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85734752021-11-09 Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL” Tong, Wing H. Technol Cancer Res Treat Letter to the Editor SAGE Publications 2021-11-05 /pmc/articles/PMC8573475/ /pubmed/34738840 http://dx.doi.org/10.1177/15330338211049902 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Tong, Wing H. Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL” |
| title | Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL” |
| title_full | Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL” |
| title_fullStr | Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL” |
| title_full_unstemmed | Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL” |
| title_short | Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL” |
| title_sort | comment on “correlation of l-asp activity, anti-l-asp antibody, asn and gln with adverse events especially anaphylaxis risks in peg-asp-contained regime treated pediatric all” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573475/ https://www.ncbi.nlm.nih.gov/pubmed/34738840 http://dx.doi.org/10.1177/15330338211049902 |
| work_keys_str_mv | AT tongwingh commentoncorrelationoflaspactivityantilaspantibodyasnandglnwithadverseeventsespeciallyanaphylaxisrisksinpegaspcontainedregimetreatedpediatricall |